Algeciras

This research aims to evaluate whether adding a mobile health (mHealth) intervention to usual care can improve recovery from difficulty swallowing (dysphagia) in patients who have had a stroke. Dysphagia affects up to 80% of stroke patients and is linked to serious complications like malnutrition, dehydration, pneumonia, and reduced quality of life. The study focuses on helping patients improve swallowing ability and reduce these negative outcomes through early and continued support at home. Participants will be assigned to either receive usual care alone or usual care plus a validated mobile app called "DegluApp." This app provides personalized guidance on nutrition, physical activity, rehabilitation exercises, warning signs, and interactive games tailored for people recovering from post-stroke dysphagia. The intervention is delivered via smartphone or tablet and aims to empower patients and their families in managing recovery. Throughout the study, participants will be monitored at multiple time points including day 1, 3 months, 6 months, and 9 months to assess swallowing improvement, allowed swallowing volume, texture tolerance, and acceptable viscosity. Researchers will track recovery progress, quality of life changes, and any reductions in complications like pneumonia and dehydration. The total participation duration includes these follow-up assessments to ensure comprehensive evaluation of the mHealth intervention's impact.

Breast cancer is a common tumor in women, often treated with surgery and therapies like chemotherapy and radiotherapy. After surgery, some women develop axillary web syndrome (AWS), a condition where a painful lymphatic cord appears in the armpit or arm, limiting shoulder movement and delaying cancer treatments. This study aims to explore if manual therapy, including kinesitherapy and stretching, can reduce the duration of AWS and improve upper limb function and quality of life for women after breast cancer surgery. Participants will be divided into two groups. The intervention group will receive 15 sessions of assisted passive kinesitherapy and scar massage over three weeks, with gentle stretches to improve shoulder mobility and reduce pain. The control group will be given instructions for self-performed active assisted kinesitherapy exercises to do daily at home, along with hygienic-postural care. Both groups will be assessed regularly, and patients with lymphedema will receive additional physical therapy after the study treatment. During the study, participants will undergo evaluations of their arm movement using goniometry, pain scales, and physical activity questionnaires at several time points up to 90 days. Researchers will monitor shoulder range of motion, pain levels, quality of life, and the time it takes for the lymphatic cord to resolve. Safety and treatment adherence will also be tracked to understand the impact of physiotherapy on AWS recovery and timely cancer treatment completion.

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy for patients aged 12 to 65 years who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, caused by sensitization to house dust mites Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. This is a double-blinded, placebo-controlled, multicenter Phase 3 trial involving 150 participants to determine the treatment's impact over one year. Participants are randomly assigned to one of three groups: two active treatment groups receiving purified allergenic extracts with concentrations of either 10,000 UT/mL or 30,000 UT/mL, and one placebo group receiving a similar solution without active ingredients. All treatments are given via subcutaneous injections as part of a one-year medication regimen. Throughout the study, participants will use a smartphone to record symptoms and medication use. Researchers will monitor combined symptoms and medication scores over 12 months. Participants will be regularly assessed for safety, treatment adherence, and allergic reactions. The study aims to measure improvements in allergic symptoms and medication needs while ensuring safety during the treatment period.

Primary immune thrombocytopenia (PIT), formerly known as idiopathic thrombocytopenic purpura, is a condition where the body destroys platelets faster than they are produced, leading to low platelet counts. The causes of PIT are not well understood, and patients show a wide range of symptoms and treatments. Diagnosis is typically made by ruling out other causes of low platelet counts. Due to limited data on how common PIT is, especially in Spain, this study aims to improve knowledge about the disease and better describe the characteristics of patients with PIT and other immune thrombocytopenias in Spain. This epidemiological study is ambispective and involves multiple hospitals in Spain. It collects information from patients' medical records about their disease and treatments since 2015. The study includes children as young as 2 months and adults who have been followed since 2015, regardless of when they were diagnosed. For deceased patients after December 31, 2015, data will still be included even if informed consent cannot be obtained. Participants contribute data from their clinical history for analysis. Researchers will describe the clinical and laboratory features of PIT and other immune thrombocytopenias starting from enrollment. The study monitors patient information to better understand the disease and its management. There are no specific treatment interventions or procedures since this is an observational registry study.